Taking Wegovy Every 2 Weeks: Why the Dosing Schedule Matters

What the trial data was actually built on

The STEP 1 trial (the foundational evidence for Wegovy's UK licence) enrolled 1,961 adults with obesity or overweight and a weight-related condition, all receiving a 2.4 mg weekly semaglutide injection for 68 weeks. Average weight reduction was around 15%. That figure is inseparable from the weekly schedule; every pharmacokinetic model, every efficacy measurement, every safety observation in that programme assumed a seven-day dosing interval. The NHS semaglutide medicines page reflects this, describing Wegovy as a once-weekly injection without exception.

There is no equivalent trial studying fortnightly semaglutide for weight management. When people ask whether taking Wegovy every two weeks is viable, the honest answer is that we simply do not have robust, peer-reviewed data on it, and that absence is itself meaningful.

One common misconception is that halving the dose frequency roughly halves the side effects while preserving most of the benefit. The pharmacology doesn't support that. Semaglutide's appetite-suppressing effect depends on sustained blood concentrations. Drop below the therapeutic range and hunger signals recover; the gastrointestinal adaptation you went through during titration may also partially reset.

How semaglutide's half-life explains the problem

Semaglutide has a plasma half-life of around one week. That is precisely why it was designed as a once-weekly medicine: a single injection maintains steady-state concentrations across seven days before the next dose. Extend the interval to fourteen days and concentrations fall substantially in the second week, well outside the range that produces meaningful appetite suppression and metabolic effect in the studied population.

This matters practically. Some people find early weeks difficult and wonder whether spacing doses out might ease nausea. It is an understandable thought. But nausea from GLP-1 medicines is largely a feature of rising drug levels; once concentrations stabilise, most people find it settles without any change to the schedule. Spreading doses further does not eliminate nausea, it tends to recreate the rising-level experience each time, because you are never reaching steady state.

If side effects are genuinely difficult, that conversation belongs with your prescriber. Pausing a dose increase, staying longer at a lower strength, or reviewing diet and timing are all options that keep you within the licensed framework. A longer dosing gap is not one of them. You can read more about how semaglutide works and the physiology behind its effect on appetite.

What to do if you have already missed a dose

Missing a single dose occasionally is not unusual. The Patient Information Leaflet gives clear guidance: if fewer than five days have passed since the day you should have injected, take the missed dose as soon as you remember and continue on your usual weekly schedule. If more than five days have passed, skip the missed dose entirely and inject on your next scheduled day. Do not take two doses to compensate.

If a pattern of missed or delayed doses is developing (whether from side effects, supply interruption, or any other reason) that is worth discussing with your clinical team rather than improvising a new schedule. For context on how supply and dose management work in practice, our frequently asked questions covers a number of real-world scenarios patients raise.

Some people also ask about taking Wegovy every five days rather than seven as a way to front-load coverage; the considerations there are different and covered separately on the taking Wegovy every five days page. The broader question of whether taking Wegovy every other week could ever be appropriate is explored in detail at can you take Wegovy every two weeks.

The clinical and regulatory position, and what to do next

The MHRA licence for Wegovy specifies weekly subcutaneous injection. No UK regulatory body has approved a fortnightly regimen for semaglutide weight management, and NICE's appraisal of semaglutide (TA875) was conducted on the licensed weekly schedule. Prescribers working within GPhC standards are not in a position to recommend a fortnightly pattern as equivalent to the assessed treatment.

If cost is part of the reason you are considering stretching doses, it is worth knowing that the price difference between fortnightly and weekly use comes at the expense of efficacy that the clinical evidence does not support at that frequency. Our Wegovy price comparison page sets out what legitimate private treatment actually costs in the UK and what a fair price includes, which is more than just the pen.

If you are already on Wegovy and something has changed (whether that is how you are tolerating it, your supply situation, or your weight progress) the right step is to contact your prescriber rather than adjust the schedule independently. At nume, a free consultation connects you with a GPhC-registered Independent Prescriber who reviews your full clinical picture. Real clinical oversight, not a chatbot making the call.